LEADS BIOLABS-B (09887) Core Product Vilixin Granted Orphan Drug Designation in Japan

LEADS BIOLABS-B (09887) announced that the company's core product Vilixin (opamtisumab, a PD-L1/4-1BB bispecific antibody) has been granted orphan drug designation by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). This is the third orphan drug designation obtained by Vilixin following those from the U.S. Food and Drug Administration (FDA) and the European Commission (EC), marking a further expansion of Vilixin's global regulatory recognition footprint into a major Asian market. With this designation, Vilixin will enjoy a series of incentives in Japan, including clinical development funding grants, professional guidance and advice from the MHLW and other agencies, priority consultation and priority review pathways, reduced consultation and marketing application fees, and extended re-examination periods. These incentives are expected to accelerate the development, registration, and commercialization of Vilixin in Japan. In 2025, Japan is the world's fourth-largest pharmaceutical market, with a market size exceeding US$73 billion. Its oncology immunotherapy market exceeds US$8 billion, ranking behind only the United States, China, and Europe. By entering this strategic market with orphan drug designation, Vilixin represents not only a breakthrough for the EP-NEC indication, but also means the company has established a policy pathway for priority communication and accelerated review within Japan's regulatory system, which will facilitate the development and registration of Vilixin's other oncology indications in Japan going forward.